58 results
SC TO-T
EX-99
MOR
Morphosys AG
11 Apr 24
Third party tender offer statement
6:01am
584(a). 11—A financial institution as defined under section 581. 12—A middleman known in the investment community as a nominee or custodian. 13
SC TO-T
EX-99
MOR
Morphosys AG
11 Apr 24
Third party tender offer statement
6:01am
and sustainability in an underserved community in the US.
Professional experience
Co-founder and CEO, Shirley Proctor Puller Foundation, US (from 2019
6-K
EX-99.1
MOR
Morphosys AG
20 Mar 24
Current report (foreign)
4:12pm
of pivotal trials ahead of schedule and presenting data at key scientific conferences – resulting in positive feedback and excitement from the cancer community … point to a paradigm shift in myelofibrosis treatment, progress long awaited by physicians and the myelofibrosis community. Updated results from
SC14D9C
EX-99.1
MOR
Morphosys AG
15 Mar 24
Written communication relating to third party tender offer
4:46pm
phase 3 MANIFEST-2 results were presented at the ASH Annual Meeting in December 2023, the myelofibrosis physician community has consistently stated
SC14D9C
EX-99.2
MOR
Morphosys AG
14 Mar 24
Written communication relating to third party tender offer
4:52pm
were Improved with Pelabresib and Ruxolitinib Combination in Phase 3 MANIFEST-2 Study Physician community has shown strong support for study results
6-K
EX-99.2
6j2j2uxgbjis4l7imia
14 Mar 24
Current report (foreign)
8:27am
6-K
EX-99.1
b76z35m6
13 Mar 24
Current report (foreign)
4:08pm
6-K
EX-99.3
wqxwyrx oh9qbbd
14 Dec 23
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
12:29pm
6-K
EX-99.2
o7mcn estd01j
20 Nov 23
Current report (foreign)
4:55pm
F-3ASR
EX-4.4
ygn60fhngc60i0j
16 Nov 23
Automatic shelf registration (foreign)
9:27am
6-K
EX-99.1
khhywbobe mg
16 Nov 23
Half-Year Report JANUARY – JUNE
9:25am
6-K
EX-99.1
i3wi9bqycs6au54ddn11
16 Nov 23
Third Quarter Interim Statement JANUARY – SEPTEMBER 2023
6:00am
6-K
EX-99.1
uc3t 3sxkan0c0wt
2 Nov 23
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
9:20am
6-K
EX-99.1
v3a42jphaj0p1o5e5
10 Aug 23
Half-Year Report JANUARY – JUNE 2023
8:51am
6-K
EX-99.1
w6ouia sq
4 May 23
First Quarter Interim Statement January – March
9:24am
6-K
EX-99.1
kzrpof7k
4 Apr 23
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
4:09pm
6-K
EX-99.2
hcmugo
17 Nov 22
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
10:37am
6-K
EX-99.1
r2v42 rvn9eotoz8e7p
16 Nov 22
Third Quarter Interim Statement January – September
4:14pm
6-K
EX-99.2
u83v9httwipe
14 Nov 22
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
6:37am